Duloxetine: Clinical Overview
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) FDA-approved for major depressive disorder, generalized anxiety disorder (in adults and children ≥7 years), diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults. 1
FDA-Approved Indications
Duloxetine is indicated for:
- Major depressive disorder (MDD) in adults
- Generalized anxiety disorder (GAD) in adults and pediatric patients ≥7 years
- Diabetic peripheral neuropathic pain (DPNP) in adults
- Fibromyalgia in adults
- Chronic musculoskeletal pain in adults 1
Dosing Recommendations
Major Depressive Disorder (Adults)
- Start: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or 30 mg twice daily)
- For tolerability concerns, start at 30 mg once daily for 1 week, then increase to 60 mg once daily
- Maximum studied dose: 120 mg/day, but no evidence that doses >60 mg/day provide additional benefit 1
Generalized Anxiety Disorder
Adults <65 years:
- Start: 60 mg once daily (or 30 mg once daily for 1 week if tolerability is a concern)
- Maximum: 120 mg/day in 30 mg increments if needed 1
Geriatric patients (≥65 years):
- Start: 30 mg once daily for 2 weeks, then increase to 60 mg/day
- Titrate in 30 mg increments if needed; maximum studied: 120 mg/day 1
Pediatric patients (7-17 years):
- Start: 30 mg once daily for 2 weeks before increasing to 60 mg once daily
- Recommended range: 30-60 mg once daily
- Maximum studied: 120 mg/day 1
Diabetic Peripheral Neuropathic Pain
- Dose: 60 mg once daily
- No evidence that doses >60 mg/day provide additional benefit, and higher doses are less well tolerated 1
- For patients with renal impairment (common in diabetes), consider lower starting dose and gradual titration 1
- Guideline recommendation: Duloxetine is a first-line agent alongside pregabalin and gabapentin 2
Fibromyalgia
- Start: 30 mg once daily for 1 week, then increase to 60 mg once daily
- Target dose: 60 mg once daily
- No evidence that doses >60 mg/day provide additional benefit 1
Neuropathic Pain (General)
- Duloxetine is recommended as a first-line medication for neuropathic pain, particularly painful diabetic neuropathy 3
- Dosing: 60 mg once daily is as effective as 60 mg twice daily 3
- Most common adverse effect is nausea, which can be reduced by starting at 30 mg once daily for 1 week before increasing to 60 mg 3
Administration Guidelines
- Take with or without food; swallow capsules whole
- Do not chew, crush, or open capsules (affects enteric coating)
- If a dose is missed, take as soon as remembered unless it's almost time for the next dose; never double dose 1
Contraindications
Absolute contraindications:
- Concomitant use with MAOIs (increased risk of serotonin syndrome) 4
- Uncontrolled narrow-angle glaucoma
- Severe hepatic impairment 1
- Severe renal impairment (CrCl <30 mL/min) 1
Precautions and Monitoring
Hepatic Concerns
- Duloxetine has been associated with hepatic failure presenting as abdominal pain, hepatomegaly, and elevated transaminases 4
- Discontinue immediately and do not restart if jaundice or clinically significant liver dysfunction develops 4
- However, routine aminotransferase monitoring is not necessary 3
Severe Skin Reactions
- Erythema multiforme and Stevens-Johnson syndrome can occur 4
- Discontinue immediately and do not restart at first appearance of blisters, peeling rash, mucosal erosions, or hypersensitivity signs 4
Cardiovascular Monitoring
- Monitor blood pressure and pulse regularly, as duloxetine can cause sustained hypertension and increased heart rate 4
- Unlike venlafaxine, duloxetine does not produce clinically important ECG changes 3
Psychiatric Monitoring
- Black box warning: Increased risk of suicidal thinking and behavior in patients ≤24 years 4
- Monitor for behavioral activation, agitation, hypomania, or mania 4
Pediatric Monitoring
- Monitor height, weight, pulse, and blood pressure
- No specific laboratory tests recommended 4
Renal Impairment
- Use lower starting dose and gradual titration in patients with renal impairment
- Particularly important in diabetic patients (frequently have renal disease) 1
Common Adverse Effects
Most common (≥5% and twice placebo rate):
- Nausea (23%) - most common reason for discontinuation 1
- Dry mouth (13%)
- Somnolence (10%)
- Constipation (9%)
- Fatigue (9%)
- Insomnia (9%)
- Dizziness (9%)
- Decreased appetite (7%)
- Hyperhidrosis (6%)
- Headache (14%) 1
Gastrointestinal effects:
- Nausea, vomiting, diarrhea, abdominal discomfort 4
Neurological effects:
- Dizziness, headache, tremor, somnolence 4
Other effects:
- Diaphoresis, decreased appetite, weight loss 4
- Sexual dysfunction (erectile dysfunction, delayed ejaculation, decreased libido, abnormal orgasm) 1
Serious but Rare Adverse Effects
- Serotonin syndrome
- Seizures
- Abnormal bleeding
- Hypomania/mania
- Suicidal ideation (particularly in patients ≤24 years) 4
Drug Interactions
Major Interactions
- MAOIs: Absolutely contraindicated due to serotonin syndrome risk 4
- CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): Avoid concomitant use 4
- CYP2D6 substrates with narrow therapeutic index: Use with caution, as duloxetine is a moderate CYP2D6 inhibitor 4
Pharmacokinetic Profile
- Duloxetine is metabolized by CYP1A2 and CYP2D6
- It is a moderate inhibitor of CYP2D6
- Minimal effect on CYP3A, CYP1A2, CYP2C9, or CYP2C19 4
Discontinuation
Duloxetine requires slow taper to avoid discontinuation syndrome 4
Discontinuation symptoms include:
- Nausea (most common)
- Dizziness
- Other withdrawal symptoms 4
Taper gradually rather than abrupt cessation to minimize discontinuation-emergent adverse events 3, 4
Duration of Treatment
Major Depressive Disorder
- First episode: Continue for 4-9 months after satisfactory response 5
- Recurrent depression (≥2 episodes): Consider longer duration 5
- Periodically reassess need for maintenance treatment 1
Neuropathic Pain
Clinical Pearls
Key advantages of duloxetine:
- Simple dosing (once daily for most indications)
- No clinically important ECG changes (unlike venlafaxine) 3
- Effective across multiple pain and psychiatric conditions
- Long elimination half-life (12 hours) permits once-daily dosing 4
Common pitfalls to avoid:
- Starting at full dose (60 mg) without titration increases nausea risk
- Always start at 30 mg for 1 week to improve tolerability 3, 1
- Combining with MAOIs or potent CYP1A2 inhibitors
- Abrupt discontinuation (always taper)
- Using in patients with severe hepatic or renal impairment
- Ignoring early signs of hepatotoxicity or severe skin reactions
Special populations: